(3S,4R)-3-((1R)-1-{[tert-butyl-(dimethyl)-silyl]-oxy}-ethyl)-4-{2-[3-(2-hydroxyethyl)-phenyl]-2-oxoethyl}-azetidin-2-one | 524071-66-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: (3S,4R)-3-((1R)-1-{[tert-butyl-(dimethyl)-silyl]-oxy}-ethyl)-4-{2-[3-(2-hydroxyethyl)-phenyl]-2-oxoethyl}-azetidin-2-one
• 英文别名: (3S,4R)-3-((1R)-1-{[tert-Butyl(dimethyl)silyl]oxy}ethyl)-4-{2-[3-(2-hydroxyethyl)phenyl]-2-oxoethyl}azetidin-2-one；(3S,4R)-3-[(1R)-1-[tert-butyl(dimethyl)silyl]oxyethyl]-4-[2-[3-(2-hydroxyethyl)phenyl]-2-oxoethyl]azetidin-2-one
• CAS: 524071-66-7
• 化学式: C₂₁H₃₃NO₄Si
• 分子量: 391.583
• InChiKey: WPKONZPAMOLMNJ-LSBZLQRGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.32
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3S,4R)-3-((1R)-1-{[tert-butyl-(dimethyl)-silyl]-oxy}-ethyl)-4-{2-[3-(2-hydroxyethyl)-phenyl]-2-oxoethyl}-azetidin-2-one 在 ruthenium trichloride sodium periodate 作用下， 以 水 、 丙酮 为溶剂， 反应 3.5h， 生成 (3-{[(2R,3S)-3-((1R)-1-{[tert-butyl-(dimethyl)-silyl]-oxy}-ethyl)-4-oxoazetidin-2-yl]-acetyl}-phenyl)-acetic acid
  参考文献：
  名称：

  EP1443047

  摘要：

  公开号：

文献信息

• Novel carbapenem compounds
  申请人：Sunagawa Makoto

  公开号：US20050020566A1

  公开（公告）日：2005-01-27

  A compound or its pharmaceutically acceptable salt represented by the following formula: The invention is a carbapenem compound which has a potent antibacterial activity over a broad range of Gram negative and Gram positive bacteria, especially penicillin-resistant Streptococcus pneumoniae (PRSP) which has been isolated at an elevated frequency in recent years and thus causes a serious clinical problem, and Haemophilus influenzae which has acquired resistance against the existing β-lactam antibiotics over a wide scope due to penicillin-binding protein (PBP) mutations such as β-lactamase non-producing ampicillin-resistant (BLNAR) Haemophilus influenzae, and has excellent oral absorbability.

  以下是化合物或其药学上可接受的盐的化学式： 该发明是一种羧甲基青霉烯化合物，具有广谱的抗革兰氏阴性和革兰氏阳性细菌的强效抗菌活性，特别是耐青霉素的肺炎链球菌（PRSP），这些菌株在近年来被高频率地分离出来，因此引起了严重的临床问题，以及流感嗜血杆菌，由于青霉素结合蛋白（PBP）突变，如β-内酰胺酶非产生性氨苄西林耐药（BLNAR）流感嗜血杆菌而对现有的β-内酰胺类抗生素产生了抗药性，并且具有优异的口服吸收性。
• Carbapenem compounds
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：US07205291B2

  公开（公告）日：2007-04-17

  A compound or its pharmaceutically acceptable salt represented by the following formula: The invention is a carbapenem compound which has a potent antibacterial activity over a broad range of Gram negative and Gram positive bacteria, especially penicillin-resistant Streptococcus pneumoniae (PRSP) which has been isolated at an elevated frequency in recent years and thus causes a serious clinical problem, and Haemophilus influenzae which has acquired resistance against the existing β-lactam antibiotics over a wide scope due to penicillin-binding protein (PBP) mutations such as β-lactamase non-producing ampicillin-resistant (BLNAR) Haemophilus influenzae, and has excellent oral absorbability.

  以下是该文本的中文翻译： 一种化合物或其药学上可接受的盐，其化学式如下所示：本发明是一种碳青霉烯化合物，具有强大的抗菌活性，可对广泛的革兰氏阴性菌和革兰氏阳性菌起作用，特别是对近年来频繁分离的耐青霉素链球菌（PRSP）和已经由于青霉素结合蛋白（PBP）突变而对现有β-内酰胺类抗生素产生抗性的β-内酰胺酶非产生性氨苄青霉素耐药（BLNAR）流感嗜血杆菌具有优异的口服吸收性，而这些细菌也是造成严重临床问题的原因。
• EP1443047
  申请人：——

  公开号：——

  公开（公告）日：——